United States· US:0074-8300_9c9f7a2c-c686-4a89-b15d-cfd58ea603d5
Skyrizi
A medicinal product containing risankizumab-rzaa, registered in United States by AbbVie Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- risankizumab-rzaa
- Manufacturer
- AbbVie Inc.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc1100748300011 SYRINGE in 1 CARTON (0074-8300-01) / 1.2 mL in 1 SYRINGE
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Risankizumab-rzaa in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSKYRIZIAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- FinlandSkyriziAbbVie Deutschland GmbH&Co.KG
- IrelandSkyrizi 150 mg Solution for injectionAbbVie Deutschland GmbH & Co. KG
- BelgiumSkyrizi 150 mgAbbVie Deutschland
- SwedenSkyrizi 150 mg Injektionsvätska, lösning i förfylld injektionspennaAbbVie Deutschland GmbH & Co KG
- IcelandSkyriziAbbVie Deutschland GmbH & Co. KG
- NetherlandsSkyrizi 150 mg, oplossing voor injectie in voorgevulde penAbbVie Deutschland GmbH & Co. KG
- SwitzerlandSkyrizi 150 mg, lnjektionslösung in einer FertigspritzeAbbVie AG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Skyrizi
- Iceland · Skyrizi
- Liechtenstein · Skyrizi
- Norway · Skyrizi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ec353739-e00f-487d-b5fe-5b7cd83c9d10 GET /v1/drugs/ec353739-e00f-487d-b5fe-5b7cd83c9d10?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 5
},
"productid": "0074-8300_9c9f7a2c-c686-4a89-b15d-cfd58ea603d5",
"productndc": "0074-8300",
"dosage_form": "INJECTION",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "RISANKIZUMAB",
"proprietary_name": "Skyrizi",
"active_ingred_unit": "mg/1.2mL",
"application_number": "BLA761105",
"marketing_category": "BLA",
"nonproprietary_name": "risankizumab-rzaa",
"start_marketing_date": "20250903",
"active_numerator_strength": "180"
}See everything about risankizumab-rzaa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.